Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Mechelen, België; 15 januari 2010 - Galapagos NV (Euronext: GLPG) kondigt vandaag aan dat zij mijlpalen heeft bereikt in de twee allianties met Merck & Co., Inc (Merck). Met dit resultaat...
-
Mechelen, Belgium; 15 January 2010 - Galapagos NV (Euronext: GLPG) announced today that it has reached milestones in both of its global strategic alliances with an affiliate of Merck & Co., Inc...
-
EpiCept Announces Reverse Split of Common Stock TARRYTOWN, N.Y.--(BUSINESS WIRE)-- Regulatory News: EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) (the “Company”) announced...
-
EpiCept Announces Executive Departure TARRYTOWN, N.Y.--(BUSINESS WIRE)-- Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced today the departure of Michael Chen,...
-
CLEVELAND, Jan. 14, 2010 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it has filed a shelf registration statement with the Securities and Exchange Commission ("SEC"). Athersys...
-
ANN ARBOR, Mich., Jan. 14, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today...
-
SALT LAKE CITY, Jan. 14, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that the Company is scheduled to give a presentation entitled: "Extensive 5-FU Inter-Patient...
-
PHILADELPHIA, Jan. 14, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced that it has provided an un-restricted grant to the International...
-
PRINCETON, N.J., Jan. 14, 2010 (GLOBE NEWSWIRE) -- Orchid Cellmark Inc. (Nasdaq:ORCH), a leading international provider of identity DNA testing services, today announced a planned consolidation of the...
-
PHILADELPHIA, Jan. 14, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company") stated that on January 14, 2010, the Company submitted reports of new preclinical data...